Indivior (NASDAQ:INDV) Shares Down 5.9%

Indivior PLC (NASDAQ:INDV) fell 5.9% during trading on Thursday . The stock traded as low as $11.37 and last traded at $11.42. 497,046 shares were traded during mid-day trading, an increase of 65% from the average session volume of 300,742 shares. The stock had previously closed at $12.14.

Analyst Ratings Changes

INDV has been the subject of several research reports. Piper Sandler started coverage on Indivior in a research report on Tuesday, July 23rd. They issued an “overweight” rating and a $22.00 price objective for the company. Craig Hallum decreased their price target on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th.

Indivior Trading Down 6.7 %

The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.68 and a current ratio of 0.85. The business’s 50 day moving average price is $12.46 and its 200-day moving average price is $16.69. The company has a market cap of $1.43 billion, a price-to-earnings ratio of 1,035.00 and a beta of 0.68.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. The company had revenue of $299.00 million for the quarter, compared to the consensus estimate of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. On average, research analysts forecast that Indivior PLC will post 1.74 EPS for the current year.

Hedge Funds Weigh In On Indivior

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new position in Indivior during the 2nd quarter worth about $188,000. VELA Investment Management LLC bought a new position in Indivior in the 2nd quarter worth approximately $235,000. XTX Topco Ltd acquired a new position in Indivior during the 2nd quarter worth $249,000. Chilton Investment Co. Inc. bought a new position in Indivior in the 4th quarter valued at $263,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Indivior during the fourth quarter worth $368,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.